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Zika and chikungunya viruses were first detected in Fiji in 
2015. Examining surveillance and phylogenetic and sero-
logic data, we found evidence of low-level transmission of 
Zika and chikungunya viruses during 2013–2017, in con-
trast to the major outbreaks caused by closely related virus 
strains in other Pacific Island countries.
Zika virus and chikungunya virus (CHIKV) have caused outbreaks in several tropical regions, includ-
ing the Pacific (1). The first known Zika virus outbreak 
occurred in Yap Island (Federated States of Micronesia) 
in 2007 (2), followed by an explosive outbreak in French 
Polynesia in 2013–2014 (3), then other Pacific islands 
(4) and Latin America (5). CHIKV first appeared in the 
Pacific in 2011 (6), causing multiple outbreaks from 
2013 onward (4).
In Fiji, the first confirmed Zika virus infections were 
detected in July 2015; these were locally acquired. By 
March 2016, a total of 13 confirmed infections had been re-
ported (7). The first recorded CHIKV infection was an im-
ported case detected in March 2015 (8); 24 autochthonous 
infections were identified by June 2016 (9). CHIKV and 
Zika virus were subsequently detected in travelers return-
ing from Fiji (10,11). Outbreaks of dengue virus (DENV) 
have been recorded in Fiji (4,12), and evidence from other 
settings indicates that DENV and Zika virus can exhibit 
similar transmission characteristics in the same location 
(13). Despite enhanced surveillance, no large outbreaks 
of Zika or chikungunya were identified in Fiji, unlike in 
other settings (3,4). We describe the introduction, epidemi-
ology, and transmission of Zika virus and CHIKV in Fiji 
during 2013–2017, in a context of concurrent circulation of 
DENV (4,12).
The Study
We retrieved surveillance data for patients with prolonged 
fever (PF), defined as any fever lasting >3 days, and acute 
fever and rash (AFR) in Fiji (Figure), as well as data on 
suspected and confirmed Zika virus, CHIKV, and DENV 
infections (Appendix Table 1, https://wwwnc.cdc.gov/
EID/article/25/8/18-0524-App1.pdf). We reconstructed 
phylogenetic trees of Zika virus and CHIKV sequences 
by using Bayesian inference (Appendix Tables 2, 3). We 
recruited 778 participants in Fiji during September–No-
vember 2013 as part of a community-based serologic sur-
vey (Appendix Figure 1). We collected follow-up samples 
from the same participants in the Central Division (N = 
333) during October–November 2015. We tested serum 
samples by using a recombinant antigen-based micro-
sphere immunoassay to detect Zika virus, CHIKV, and 
DENV-1–4 IgG (Appendix). Analysis of neutralizing an-
tibodies against Zika virus and DENV in a subset of 69 
paired serum samples showed good concordance with the 
microsphere immunoassay for Zika virus (κ = 0.71) and 
DENV (κ = 0.80) (Appendix Table 4).
Surveillance data recorded during 2013–2017 indicat-
ed cyclical increases in AFR and PF each year, concurrent 
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DISPATCHES
with the hot and rainy season occurring in December–
April (Figure). Molecular testing of blood samples from 
symptomatic patients suggested outbreaks of DENV-1 in 
2013, DENV-3 in 2014, and DENV-2 in 2017. In 2015, 
Zika virus and CHIKV apparently were co-circulating at 
low levels alongside DENV-1, DENV-2, and DENV-3. 
In 2016, an increase in proportional positivity for Zika 
virus and CHIKV was detected among 804 AFR and PF 
patients, suggesting higher transmission of these viruses 
but not widespread circulation (Zika virus, 32/804 [4%]; 
CHIKV, 86/804 [11%]; DENV-2, 10/804 [1%]; DENV-
4, 2/804 [<1%]). Additional CHIKV (n = 2) and Zika vi-
rus (n = 1) infections were detected during the first half 
of 2017.
We aligned the envelope (E) gene sequences of Zika 
virus strains collected in Fiji during 2015–2016 (Ap-
pendix Table 2) with sequences from other countries. 
All Zika virus strains belonged to the Asia lineage and 
segregated into 2 separate clades (posterior probability 
>0.99) (Appendix Figure 2, panel A). The Fiji Zika virus 
strains belonged to the Asia and Oceania clade; 2 strains 
collected in 2016 grouped with viruses isolated in Japan 
in 2016 (posterior probability >0.99), including 1 from a 
traveler returning from Fiji. The estimated time of most 
recent common ancestor of this cluster was September 
2013 (95% higher probability density [HPD] interval Sep-
tember 2011–August 2015). The remaining Fiji strains 
formed a distinct cluster with strains from Southeast Asia 
and other Pacific Islands. We dated the origin of this 
second cluster to November 2013 (95% HPD interval 
March 2013–July 2015). 
We aligned the E1 gene sequences of Fiji CHIKV 
strains collected during 2015–2016 (Appendix Table 2) 
with sequences from other countries. All strains belonged 
to the Asia genotype; Fiji strains formed a monophyletic 
group with strains from Tonga sampled in 2014 (poste-
rior probability 1.00) (Appendix Figure 2, panel B). This 
grouping suggested a single introduction of CHIKV into 
Fiji in February 2014 (95% HPD interval December 2013–
August 2014) and subsequent persistence in the population.
Zika virus seroprevalence in 2013 was 7.8% (95% CI 
6.1%–10%); we observed no significant differences between 
age groups, sexes, residential divisions, or areas (Table). In 
2015, seroprevalence was 21.9% (95% CI 17.6%–26.8%), 
and the only significant difference observed was between 
rural (14.2% [95% CI 8.3%–22%]) and urban (26.6% [95% 
CI 19.5%–34.6%]) areas (p = 0.0202). Compared with 2013, 
Zika virus seroprevalence in 2015 was significantly higher 
overall (p<0.0001). However, no change was observed in the 
CHIKV seroprevalence between 2013 (0.8% [95% CI 0.3%–
1.7%]) and 2015 (0.9% [95% CI 0.2%–2.6%]), and no signif-
icant differences were observed in the demographic variables 
described for Zika virus. The seroprevalence of DENV in 
2013 was 73% (95% CI 69.7%–76.1%) and was lower among 
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Figure. Reports of patients with acute fever and rash, prolonged fever, and infections with dengue, Zika, or chikungunya viruses 
confirmed by reverse transcription PCR in Fiji, 2013–2017. Number of dengue, Zika, or chikungunya virus infections were confirmed 
by reverse transcription PCR. Asterisks (*) indicate imported chikungunya virus infections. CHIKV, chikungunya virus; DENV-1, dengue 
virus serotype 1; DENV-2, dengue virus serotype 2; DENV-3, dengue virus serotype 3; DENV-4, dengue virus serotype 4; DENV?, 
information on dengue virus serotype not available; ZIKV, Zika virus.
 Transmission of Zika and Chikungunya, Fiji Islands
persons in the 0–19 years age group compared with other age 
groups (p<0.0001) (Table). We observed no significant dif-
ference by sex. DENV seropositivity was higher in the North-
ern than in the Central and Western divisions (p<0.0368) and 
higher in urban than in rural areas (p = 0.0136). During 2013–
2015, we observed a significant increase in DENV seropreva-
lence (82.9% [95% CI 78.4%–86.8%]; p = 0.0004) among 
persons 0–19 years of age (p = 0.0013), women and girls (p 
= 0.0002), and participants living in the Central Division (p = 
0.0018) and urban areas (p = 0.0048). Seroprevalence in 2015 
remained lower in persons 0–19 years of age than in other age 
groups (p<0.0137) but was significantly higher in women and 
girls compared with men and boys (p = 0.039) and in urban 
compared with rural areas (p = 0.0053).
Analysis of paired samples collected in 2013 and 2015 
from the same participants supported previous serologic find-
ings on all samples collected (Appendix Table 5). Among 
these participants, 55/311 (17.7% [95% CI 13.6%–22.4%]) 
seroconverted to Zika virus, 40/311 (12.9% [95% CI 9.3%–
17.1%]) seroconverted to DENV, and 1/311 (0.3% [95% CI 
0.008%–1.8%]) seroconverted to CHIKV (Appendix Table 6).
Conclusions
We found evidence of low-level transmission of Zika vi-
rus and CHIKV in Fiji for multiple years after their initial 
introduction into a population that probably was immuno-
logically naive, despite an ecologic environment subject to 
large and recurrent DENV outbreaks. Similar evidence of 
low-level Zika virus circulation has been observed in other 
settings (14). Our findings indicate that Zika virus circu-
lated before the first confirmed cases in 2015 and that mul-
tiple introductions from other Pacific islands might have 
occurred, which suggests the possible role of Zika virus 
in a cluster of Guillain-Barré syndrome cases of unknown 
etiology in Fiji during February–May 2014 (15). Howev-
er, there was no epidemiologic or serologic evidence that 
CHIKV circulated in Fiji before it was first reported in 
2015. High DENV seroprevalence in 2013 and 2015 sug-
gests that DENV is endemic in Fiji, with seroprevalence 
increasing with age. Our data also suggest that DENV and 
Zika virus transmission occurs mostly in urban areas where 
peridomestic mosquitoes, notably Aedes aegypti and Ae. 
albopictus, are abundant.
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Table. Prevalence of Zika, chikungunya, and dengue virus antibodies in a representative subset of the population sampled during 
September–November 2013 and October–November 2015, Fiji Islands* 
Variable 
No. seropositive/no. tested (% [95% CI]) 
Zika virus 
 
Chikungunya virus 
 
Dengue viruses† 
2013 2015 2013 2015 2013 2015 
Total 61/778‡ 
(7.8 [6.1–10]) 
73/333  
(21.9 [17.6–26.8]) 
 6/778  
(0.8 [0.3–1.7]) 
3/333  
(0.9 [0.2–2.6]) 
 568/778  
(73 [69.7–76.1]) 
276/333  
(82.9 [78.4–86.8]) 
Age range 
(median), y 
2–85 (28) 4–80 (29)  2–85 (28) 4–80 (29)  2–78 (28) 4–80 (29) 
Age group, y 
  
 
  
 
  
 0–19 29/282  
(10.3 [7–14.4]) 
29/115  
(25.2 [17.6–34.2]) 
 4/282  
(1.4 [0.4–3.6]) 
1/115  
(0.9 [0–4.7]) 
 141/282  
(50 [44–56]) 
78/115  
(67.8 [58.5–76.2]) 
 20–39 15/239  
(6.3 [3.6–10.1]) 
18/103  
(17.5 [10.7–26.2]) 
 1/239  
(0.4 [0–2.3]) 
1/103  
(1 [0–5.3]) 
 201/239  
(84.1 [78.8–88.5]) 
93/103  
(90.3 [82.9–95.2]) 
 40–59 11/179  
(6.1 [3.1–10.7]) 
13/73  
(17.8 [9.8–28.5]) 
 1/179  
(0.6 [0–3.1]) 
1/73  
(1.4 [0–7.4]) 
 161/179 (89.9 
[84.6–93.9]) 
68/73  
(93.2 [84.7–97.7]) 
 ≥60 6/77  
(7.8 [2.9–16.2]) 
13/42  
(31 [17.6–47.1]) 
 0/77  
(0 [0–4.7]) 
0/42  
(0 [0–8.4]) 
 64/77  
(83.1 [72.9–90.7]) 
37/42  
(88.1 [74.4–96]) 
Sex 
  
 
  
 
  
 F 28/423  
(6.6 [4.4–9.4]) 
41/190  
(21.6 [16–28.1]) 
 4/423  
(0.9 [0.3–2.4]) 
2/190  
(1.1 [0.1–3.8]) 
 312/423  
(73.8 [69.3–77.9]) 
165/190  
(86.8 [81.2–91.3]) 
 M 33/354  
(9.3 [6.5–12.8]) 
32/143  
(22.4 [15.8–30.1]) 
 2/354  
(0.6 [0.1–2]) 
1/143  
(0.7 [0–3.8]) 
 255/354  
(72 [67–76.6]) 
111/143  
(77.6 [69.9–84.2]) 
Division 
  
 
  
 
  
 Central 30/451  
(6.7 [4.5–9.4]) 
73/333  
(21.9 [17.6–26.8]) 
 5/451  
(1.1 [0.4–2.6]) 
3/333  
(0.9 [0.2–2.6]) 
 331/451  
(73.4 [69.1–77.4]) 
276/333  
(82.9 [78.4–86.8]) 
 Northern 7/59  
(11.9 [4.9–22.9]) 
ND  0/59  
(0 [0–6.1]) 
ND  51/59  
(86.4 [75–94]) 
ND 
 Western 24/268  
(9 [5.8–13]) 
ND  1/268  
(0.4 [0–2.1]) 
ND  186/268  
(69.4 [63.5–74.9]) 
ND 
Area 
  
 
  
 
  
 Periurban 10/135  
(7.4 [3.6–13.2]) 
19/77  
(24.7 [15.6–35.8]) 
 2/135  
(1.5 [0.2–5.2]) 
0/77  
(0 [0–4.7]) 
 104/135  
(77 [69–83.8]) 
66/77  
(85.7 [75.9–92.6]) 
 Rural 24/344  
(7 [4.5–10.2]) 
16/113  
(14.2 [8.3–22]) 
 2/344  
(0.6 [0.1–2.1]) 
0/113  
(0 [0–3.2]) 
 234/344  
(68 [62.8–72.9]) 
84/113  
(74.3 [65.3–82.1]) 
 Urban 27/298  
(9.1 [6.1–12.9]) 
38/143  
(26.6 [19.5–34.6]) 
 2/298  
(0.7 [0.1–2.4]) 
3/143  
(2.1 [0.4–6]) 
 229/298  
(76.8 [71.6–81.5]) 
126/143  
(88.1 [81.6–92.9]) 
*No participants were recruited in the Northern and Western divisions in 2015. ND, no data. 
†Seropositivity for >1 serotypes of dengue virus. 
‡For 1 participant, demographic data were not available except for the administrative division of residence. 
 
DISPATCHES
Our study highlights the difficulties in detecting and 
anticipating outbreaks of Zika virus and CHIKV and the 
value of having multiple data sources available. Stronger 
clinical and laboratory surveillance capacities are needed 
to ensure the early detection of these and future infectious 
disease threats.
This work was part of ISID-Pacific and R-ZERO Pacific  
programs funded by the French Ministry for Europe and Foreign 
Affairs (Pacific Fund nos. 06314-09/04/14, 12115-02/09/15, 
03016-20/05/16, and 04917-19/07/17). The study also received 
support from the Embassy of France in the Republic of the Fiji 
Islands. The study was supported by the French Government’s 
“Investissement d’Avenir” Program (Labex IBEID no. ANR-
10-LABX-62-IBEID). C.L.L. was supported by an Australia 
National Health and Medical Research Council Fellowship (grant 
no. 1109035). A.J.K. was supported by a Wellcome Trust/Royal 
Society Sir Henry Dale Fellowship (grant no. 206250/Z/17/Z). 
The seroprevalence study was part of MSc research work by M.K. 
performed at the University of the South Pacific.
About the Author
Dr. Kama is a medical doctor with the Fiji Ministry of Health. 
Since 2008, he has worked in communicable disease control 
in Fiji. His area of interest is public health surveillance and 
response to communicable disease emergencies.
References
  1. Cao-Lormeau V-M. Tropical islands as new hubs for emerging  
arboviruses. Emerg Infect Dis. 2016;22:913–5. http://dx.doi.
org/10.3201/eid2205.150547
  2. Duffy MR, Chen T-H, Hancock WT, Powers AM, Kool JL,  
Lanciotti RS, et al. Zika virus outbreak on Yap Island, Federated 
States of Micronesia. N Engl J Med. 2009;360:2536–43  
http://dx.doi.org/10.1056/NEJMoa0805715
  3. Cao-Lormeau V-M, Roche C, Teissier A, Robin E, Berry A-L, 
Mallet H-P, et al. Zika virus, French Polynesia, South Pacific, 2013. 
Emerg Infect Dis. 2014;20:1085–6. http://dx.doi.org/10.3201/
eid2011.141380
  4. Cao-Lormeau V-M, Musso D. Emerging arboviruses in the  
Pacific. Lancet. 2014;384:1571–2. http://dx.doi.org/10.1016/
S0140-6736(14)61977-2
  5. Ikejezie J, Shapiro CN, Kim J, Chiu M, Almiron M, Ugarte C,  
et al. Zika virus transmission—Region of the Americas,  
May 15, 2015–December 15, 2016. MMWR Morb Mortal  
Wkly Rep. 2017;66:329–34. http://dx.doi.org/10.15585/ 
mmwr.mm6612a4
  6. Dupont-Rouzeyrol M, Caro V, Guillaumot L, Vazeille M,  
D’Ortenzio E, Thiberge J-M, et al. Chikungunya virus and the 
mosquito vector Aedes aegypti in New Caledonia (South Pacific 
Region). Vector Borne Zoonotic Dis. 2012;12:1036–41.  
http://dx.doi.org/10.1089/vbz.2011.0937
  7. Fiji Ministry of Health and Medical Services. Fiji Ministry of 
Health and Medical Services travel advice [cited 2018 Jan 31]. 
http://www.health.gov.fj/wp-content/uploads/2016/02/Fiji- 
Ministry-of-Health-Travel-Advice.pdf
  8. Fiji Ministry of Health and Medical Services. Chikungunya alert 
[cited 2018 Jan 31]. http://www.health.gov.fj/?p=4366
  9. Fiji Ministry of Health and Medical Services. People continue to 
support Fight the Bite—Clean Up Fiji campaign [cited 2018 Jan 
31]. http://www.health.gov.fj/?p=5751
10. Institute of Environmental Science and Research Limited. Zika 
virus infection weekly report, 27 February 2017 [cited 2018 Jan 
31]. https://surv.esr.cri.nz/PDF_surveillance/ZikaWeekly/2017/ 
20170227Zikaweekly.pdf
11. Australian Government Department of Health. Summary  
information about overseas-acquired vectorborne disease  
notifications in Australia [cited 2018 Jan 31]. http://www.health.
gov.au/internet/main/publishing.nsf/Content/F4E393746A4B690F
CA2580D4007DB251/$File/13-Jan-18-overseas-notifications.pdf
12. Kucharski AJ, Kama M, Watson CH, Aubry M, Funk S,  
Henderson AD, et al. Using paired serology and surveillance data 
to quantify dengue transmission and control during a large  
outbreak in Fiji. eLife. 2018;7:e34848. http://dx.doi.org/10.7554/
eLife.34848
13. Funk S, Kucharski AJ, Camacho A, Eggo RM, Yakob L, Murray LM,  
et al. Comparative analysis of dengue and Zika outbreaks 
reveals differences by setting and virus. PLoS Negl Trop Dis. 
2016;10:e0005173. http://dx.doi.org/10.1371/journal. 
pntd.0005173
14. Ruchusatsawat K, Wongjaroen P, Posanacharoen A,  
Rodriguez-Barraquer I, Sangkitporn S, Cummings DAT, et al. 
Long-term circulation of Zika virus in Thailand: an observational  
study. Lancet Infect Dis. 2019;19:439–46. http://dx.doi.org/10.1016/ 
S1473-3099(18)30718-7
15. Pastula DM, Khan AS, Sharp TM, Biaukula VL, Naivalu TK,  
Rafai E, et al. Investigation of a Guillain-Barré syndrome  
cluster in the Republic of Fiji. J Neurol Sci. 2017;372:350–5.  
http://dx.doi.org/10.1016/j.jns.2016.08.064
Address for correspondence: Van-Mai Cao-Lormeau, Institut Louis 
Malardé, PO Box 30, 98713 Papeete, Tahiti; email: mlormeau@ilm.pf
1538 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 25, No. 8, August 2019
